Open company research · RGEN
Repligen
Filtration, chromatography and process analytics
Sources checked 2026-10-21 · Source review; evidence limits noted belowResearch question
Validated downstream purification and fluid-management throughput
What limits delivery, and how quickly can qualified alternatives expand?
Reported evidence
Repligen describes filtration systems, pre-packed chromatography columns, fluid management and process analytics for biologics.
- Repligen: bioprocessing product portfolio ↗Source: date not provided · Checked 2026-10-21
- Repligen: Q2 2026 results ↗Source: 2026-07-28 · Checked 2026-10-21
Our interpretation
Workflow relevance does not establish exclusive supply or a current industry-wide shortage.
Capacity and delivery
- The cited product documentation does not quantify current customer-accepted annual output. Source ↗
What to monitor
- Validated column and filtration demand versus customer inventories
- GAAP profitability, order conversion and recurring consumables
What would weaken the case?
- Competing purification technologies reduce spend per batch
- Customer capacity additions outpace biologics demand
Reported financial exposure
- Total revenue
- 204,128 USD thousandQ2 2026 · GAAP · Source ↗
- Income from operations
- 13,976 USD thousandQ2 2026 · GAAP · Source ↗
Constraint-specific revenue, pricing power and valuation are not quantified. Product relevance does not establish pure-play exposure.
Valuation and the share of revenue attributable to this specific constraint are not quantified here. GAAP, adjusted and segment measures retain their source definitions.Continue in the Atlas →